User profiles for M. Aldea

Martí Aldea Malo

Research Professor
Verified email at ibmb.csic.es
Cited by 7510

Tumour burden and efficacy of immune-checkpoint inhibitors

…, C Caramella, C Garcia, M Aldea… - Nature reviews Clinical …, 2022 - nature.com
Accumulating evidence suggests that a high tumour burden has a negative effect on anticancer
immunity. The concept of tumour burden, simply defined as the total amount of cancer in …

Multiple pathways to functional impairment in obsessive–compulsive disorder

Y Markarian, MJ Larson, MA Aldea, SA Baldwin… - Clinical psychology …, 2010 - Elsevier
Obsessive–compulsive disorder (OCD) is a chronic and debilitating condition that is relatively
common in both children and adults, and it is associated with a wide range of functional …

Overcoming resistance to tumor-targeted and immune-targeted therapies

M Aldea, F Andre, A Marabelle, S Dogan, F Barlesi… - Cancer Discovery, 2021 - AACR
A better and earlier identification of cancer-resistance mechanisms could avoid the use of
ineffective drugs in patients not responding to therapy and provide the rationale for the …

[HTML][HTML] Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled …

…, MTG Morales, E Arana-Arri, M Aldea… - The Lancet, 2021 - thelancet.com
Background To date, no immunological data on COVID-19 heterologous vaccination schedules
in humans have been reported. We assessed the immunogenicity and reactogenicity of …

New method for generating deletions and gene replacements in Escherichia coli

CM Hamilton, M Aldea, BK Washburn… - Journal of …, 1989 - Am Soc Microbiol
We describe a method for generating gene replacements and deletions in Escherichia coli.
The technique is simple and rapid and can be applied to most genes, even those that are …

A Set of Vectors with a Tetracycline‐Regulatable Promoter System for Modulated Gene Expression in Saccharomyces cerevisiae

E Garí, L Piedrafita, M Aldea, E Herrero - Yeast, 1997 - Wiley Online Library
A set of Saccharomyces cerevisiae expression vectors has been developed in which
transcription is driven by a hybrid tetO‐CYC1 promoter through the action of a tetR‐VP16 (tTA) …

The yeast genome directory

…, L Alberghina, K Albermann, M Albers, M Aldea… - Nature, 1997 - nature.com
This directory was made possible by a unique international collaboration between the 633
scientists whose names appear below. It represents both the first published description of the …

An activator/repressor dual system allows tight tetracycline-regulated gene expression in budding yeast

G Bellí, E Garí, L Piedrafita, M Aldea… - Nucleic acids …, 1998 - academic.oup.com
We have developed an activator/repressor expression system for budding yeast in which
tetracyclines control in opposite ways the ability of tetR-based activator and repressor …

[HTML][HTML] 1, 25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway

A Cardus, E Parisi, C Gallego, M Aldea, E Fernandez… - Kidney international, 2006 - Elsevier
Atherosclerosis is a complex process characterized by an increase in the wall thickness
owing to the accumulation of cells and extracellular matrix between the endothelium and the …

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

…, NS Akhave, T Zhou, L Delasos, JK Hicks, M Aldea… - Cancer discovery, 2023 - AACR
In this work, we identify co-occurring genomic alterations in KEAP1 , SMARCA4 , and CDKN2A
as independent determinants of poor clinical outcomes with KRAS G12Ci monotherapy …